Tuesday, 16 December 2014
Biotech Roundup: EC Report on Pharma, Dendreon Bankruptcy, Cost of Drug Development and Tackling Failure in Pharma R&D
1. We wrote on the IPCopy blog on the complex issue of how much data is required for a biotech patent, and briefly examined how the UK Courts have dealt with the issue in recent years. See ‘When is a Biotech Invention Completed? How Much Data is Needed?’
2. The Fifth European Commission Report on Pharma Patent Settlements is available here. Willkie Farr & Gallagher’s interesting analysis on how the Report must be seen in the context of the Servier and Lundbeck cases can be found here. A response by EFPIA can be found here.
3. The Dendreon bankruptcy led to interesting analysis by Xconomy (see here), New York Times (see here) and FierceBiotech (see here).
4. The cost of developing a drug ($2.6bn) was being discussed again after new figures were release by Tufts (see here). Life Sci VC essentially agreed with the Tufts analysis and figure (see here). Forbes have a more sceptical piece on this here.
5. Xconomy wrote on ‘Lowering the Cost of Failure in Biopharmaceuticals’ which listed the mistakes that big pharma is making in managing projects.